Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

References

• Abraham MH, Austin RP. 2012. The effect of ionized species on microsomal binding. Eur J Med Chem. 47(1):202–205.
   PubMed Web of Science ®Google Scholar
• Alves DS, Perez-Fons L, Estepa A, Micol V. 2004. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem Pharmacol. 68(3):549–561.
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. 2002. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos. 30(12):1497–1503.
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Mohmed S, Riley RJ. 2005. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos. 33(3):419–425.
   PubMed Web of Science ®Google Scholar
• Avdeef A, Bendels S, Di L, Faller B, Kansy M, Sugano K, Yamauchi Y. 2007. PAMPA–critical factors for better predictions of absorption. J Pharm Sci. 96(11):2893–2909.
   PubMed Web of Science ®Google Scholar
• Barr JT, Lade JM, Tran TB, Dahal UP. 2019. Fraction unbound for liver microsome and hepatocyte incubations for all major species can be approximated using a single-species surrogate. Drug Metab Dispos. 47(4):419–423.
   PubMed Web of Science ®Google Scholar
• Beaumont K, Gardner I, Chapman K, Hall M, Rowland M. 2011. Toward an integrated human clearance prediction strategy that minimizes animal use. J Pharm Sci. 100(10):4518–4535.
   PubMed Web of Science ®Google Scholar
• Chang G, Steyn SJ, Umland JP, Scott DO. 2010. Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery. ACS Med Chem Lett. 1(2):50–53.
   PubMed Web of Science ®Google Scholar
• Chen S, Prieto Garcia L, Bergstrom F, Nordell P, Grime K. 2017. Intrinsic clearance assay incubational binding: a method comparison. Drug Metab Dispos. 45(4):342–345.
   PubMed Web of Science ®Google Scholar
• Deshmukh SV, Harsch A. 2011. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance. J Pharmacol Toxicol Methods. 63(1):35–39.
   PubMed Web of Science ®Google Scholar
• Gao H, Steyn SJ, Chang G, Lin J. 2010. Assessment of in silico models for fraction of unbound drug in human liver microsomes. Expert Opin Drug Metab Toxicol. 6(5):533–542.
   PubMed Web of Science ®Google Scholar
• Gao H, Yao L, Mathieu HW, Zhang Y, Maurer TS, Troutman MD, Scott DO, Ruggeri RB, Lin J. 2008. In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos. 36(10):2130–2135.
   PubMed Web of Science ®Google Scholar
• Gertz M, Kilford PJ, Houston JB, Galetin A. 2008. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos. 36(3):535–542.
   PubMed Web of Science ®Google Scholar
• Gouliarmou V, Lostia AM, Coecke S, Bernasconi C, Bessems J, Dorne JL, Ferguson S, Testai E, Remy UG, Brian Houston J, et al. 2018. Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance. Toxicol in Vitro. 53:233–244.
   PubMed Web of Science ®Google Scholar
• Grime KH, Barton P, McGinnity DF. 2013. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. Mol Pharm. 10(4):1191–1206.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. 2006. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos. 34(4):724–726; author reply 727.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. 2007. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos. 35(8):1325–1332.
   PubMed Web of Science ®Google Scholar
• Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 47(9):1469–1479.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. 1996. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos. 17(4):273–310.
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Gertz M, Houston JB, Galetin A. 2008. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos. 36(7):1194–1197.
   PubMed Web of Science ®Google Scholar
• Kosugi Y, Hosea N. 2020. Direct comparison of total clearance prediction: computational machine learning model versus bottom-up approach using in vitro assay. Mol Pharm. 17(7):2299–2309.
   PubMed Web of Science ®Google Scholar
• Mannhold R, Poda GI, Ostermann C, Tetko IV. 2009. Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds. J Pharm Sci. 98(3):861–893.
   PubMed Web of Science ®Google Scholar
• Mateus A, Matsson P, Artursson P. 2013. Rapid measurement of intracellular unbound drug concentrations. Mol Pharm. 10(6):2467–2478.
   PubMed Web of Science ®Google Scholar
• McLure JA, Birkett DJ, Elliot DJ, Williams JA, Rowland A, Miners JO. 2011. Application of the fluorescent probe 1-anilinonaphthalene-8-sulfonate to the measurement of the nonspecific binding of drugs to human liver microsomes. Drug Metab Dispos. 39(9):1711–1717.
   PubMed Web of Science ®Google Scholar
• Nagar S, Korzekwa K. 2012. Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics. Drug Metab Dispos. 40(9):1649–1652.
   PubMed Web of Science ®Google Scholar
• Nagar S, Korzekwa K. 2017. Drug distribution. Part 1. Models to predict membrane partitioning. Pharm Res. 34(3):535–543.
   PubMed Web of Science ®Google Scholar
• Nair PC, McKinnon RA, Miners JO. 2016. A fragment-based approach for the computational prediction of the nonspecific binding of drugs to hepatic microsomes. Drug Metab Dispos. 44(11):1794–1798.
   PubMed Web of Science ®Google Scholar
• Nordell P, Svanberg P, Bird J, Grime K. 2013. Predicting metabolic clearance for drugs that are actively transported into hepatocytes: incubational binding as a consequence of in vitro hepatocyte concentration is a key factor. Drug Metab Dispos. 41(4):836–843.
   PubMed Web of Science ®Google Scholar
• Obach RS. 1997. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos. 25(12):1359–1369.
   PubMed Web of Science ®Google Scholar
• Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 27(11):1350–1359.
   PubMed Web of Science ®Google Scholar
• Pagliara A, Carrupt PA, Caron G, Gaillard P, Testa B. 1997. Lipophilicity profiles of ampholytes. Chem Rev. 97(8):3385–3400.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M. 2007. In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica. 37(10–11):1066–1089.
   PubMed Web of Science ®Google Scholar
• Poulin P, Collet SH, Atrux-Tallau N, Linget JM, Hennequin L, Wilson CE. 2019. Application of the tissue composition-based model to minipig for predicting the volume of distribution at steady state and dermis-to-plasma partition coefficients of drugs used in the physiologically based pharmacokinetics model in dermatology. J Pharm Sci. 108(1):603–619.
   PubMed Web of Science ®Google Scholar
• Poulin P, Haddad S. 2011. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci. 100(10):4501–4517.
   PubMed Web of Science ®Google Scholar
• Poulin P, Haddad S. 2013. Hepatocyte composition-based model as a mechanistic tool for predicting the cell suspension: aqueous phase partition coefficient of drugs in in vitro metabolic studies. J Pharm Sci. 102(8):2806–2818.
   PubMed Web of Science ®Google Scholar
• Riccardi K, Ryu S, Lin J, Yates P, Tess D, Li R, Singh D, Holder BR, Kapinos B, Chang G, et al. 2018. Comparison of species and cell-type differences in fraction unbound of liver tissues, hepatocytes, and cell lines. Drug Metab Dispos. 46(4):415–421.
   PubMed Web of Science ®Google Scholar
• Riccardi K, Ryu S, Tess D, Li R, Luo L, Johnson N, Jordan S, Patel R, Di L. 2020. Comparison of fraction unbound between liver homogenate and hepatocytes at 4 degrees C. AAPS J. 22(4):91.
   PubMed Web of Science ®Google Scholar
• Riede J, Camenisch G, Huwyler J, Poller B. 2017. Current in vitro methods to determine hepatic Kpuu: a comparison of their usefulness and limitations. J Pharm Sci. 106(9):2805–2814.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci. 100(10):4090–4110.
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 95(6):1238–1257.
   PubMed Web of Science ®Google Scholar
• Rusinova R, Herold KF, Sanford RL, Greathouse DV, Hemmings HC, Jr., Andersen OS. 2011. Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery. J Gen Physiol. 138(2):249–270.
   PubMed Web of Science ®Google Scholar
• Suenderhauf C, Parrott N. 2013. A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation. Pharm Res. 30(1):1–15.
   PubMed Web of Science ®Google Scholar
• Tess DA, Ryu S, Di L. 2022. In vitro – in vivo extrapolation of hepatic clearance in preclinical species. Pharm Res. 39(7):1615–1632.
   PubMed Web of Science ®Google Scholar
• Treyer A, Ullah M, Parrott N, Molitor B, Fowler S, Artursson P. 2019. Impact of intracellular concentrations on metabolic drug-drug interaction studies. AAPS J. 21(5):77.
   PubMed Web of Science ®Google Scholar
• Turner DB, Rostami-Hodjegan A, Tucker GT, Rowland-Yeo KR. 2006. Prediction of Non-specific hepatic microsomal binding from readily available physicochemical properties. Drug Met Rev. 38(S1):162.
   Google Scholar
• Wang T, Whitcher-Johnstone A, Keith-Luzzi M, Chan TS. 2021. HLM-beads: rapid assessment of nonspecific binding to human liver microsomes using magnetizable beads. Drug Metab Dispos. 49(12):1056–1062.
   PubMed Web of Science ®Google Scholar
• Winiwarter S, Chang G, Desai P, Menzel K, Faller B, Arimoto R, Keefer C, Broccatell F. 2019. Prediction of fraction unbound in microsomal and hepatocyte incubations: a comparison of methods across industry datasets. Mol Pharm. 16(9):4077–4085.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao L, Lin J, Gao H, Wilson TC, Giragossian C. 2010. Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci. 99(8):3620–3627.
   PubMed Web of Science ®Google Scholar
• Zhou S, Kestell P, Paxton JW. 2002. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. J Pharm Pharmacol. 54(7):997–1003.
   PubMed Web of Science ®Google Scholar